Recombinant Polypeptides for Triple DAMP Cancer Immunotherapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing cancer therapies like chemotherapy and radiotherapy induce immunogenic cell death with limited efficiency by not expressing all three pre-apoptotic DAMP signals and cause adverse effects on non-tumor cells.

Innovation Solution

Development of recombinant polypeptides that express all three pre-apoptotic DAMP signals (calreticulin, HSP70, and HSP90) to enhance immunogenic cell death, minimizing adverse effects on non-tumor cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy or radiotherapy is used to induce immunogenic cell death, then some pre-apoptotic DAMP signals (CRT, HSP70, HSP90) are expressed, but not all three signals are expressed simultaneously and adverse effects occur on non-tumor cells

Engineering Contradiction:

Improveinduction of immunogenic cell deathVSAvoidcollateral damage to non-tumor cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical structure of existing immunogenic cell death inducers by changing molecular parameters (adding specific functional groups, modifying core structures) to enhance their ability to induce all three DAMP signals while reducing off-target effects on non-tumor cells

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent develops composite therapeutic agents that combine multiple pharmacophores or structural elements within a single molecular framework, enabling simultaneous induction of CRT, HSP70, and HSP90 expression while minimizing collateral damage through optimized molecular architecture

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional therapies are used, then some anti-tumor immune response is generated, but the response is insufficient because not all three DAMP signals are expressed

Engineering Contradiction:

Improveanti-tumor immune responseVSAvoidefficiency of immunogenic cell death induction

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent optimizes molecular parameters of therapeutic agents to maximize their efficacy in inducing all three pre-apoptotic DAMP signals (CRT, HSP70, HSP90) simultaneously, thereby enhancing the robustness and efficiency of the resulting anti-tumor immune response

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent designs multi-functional therapeutic agents capable of simultaneously inducing multiple DAMP signals and activating various components of the immune system, creating a comprehensive anti-tumor immune response through a single therapeutic intervention

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260062454A1Recombinant polypeptides and methods of use thereof

Publication Date: 2026.03.05 IMUNAMI LAB PTE LTD

AI summary

The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.